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Huntington’s disease (HD) is an autosomal dominant disorder caused by a tandem repeat
expansion encoding an expanded tract of glutamines in the huntingtin protein. HD is pro-
gressive and manifests as psychiatric symptoms (including depression), cognitive deficits
(culminating in dementia), and motor abnormalities (including chorea). Having reached the
twentieth anniversary of the discovery of the “genetic stutter” which causes HD, we still
lack sophisticated insight into why so many HD patients exhibit affective disorders such as
depression at very early stages, prior to overt appearance of motor deficits. In this review,
we will focus on depression as the major psychiatric manifestation of HD, discuss potential
mechanisms of pathogenesis identified from animal models, and compare depression in
HD patients with that of the wider gene-negative population.The discovery of depressive-
like behaviors as well as cellular and molecular correlates of depression in transgenic HD
mice has added strong support to the hypothesis that the HD mutation adds significantly
to the genetic load for depression. A key question is whether HD-associated depression
differs from that in the general population. Whilst preclinical studies, clinical data, and treat-
ment responses suggest striking similarities, there are also some apparent differences.We
discuss various molecular and cellular mechanisms which may contribute to depression in
HD, and whether they may generalize to other depressive disorders. The autosomal dom-
inant nature of HD and the existence of models with excellent construct validity provide
a unique opportunity to understand the pathogenesis of depression and associated gene-
environment interactions.Thus, understanding the pathogenesis of depression in HD may
not only facilitate tailored therapeutic approaches for HD sufferers, but may also translate
to the clinical depression which devastates the lives of so many people.
Keywords: Huntington’s disease, neurodegeneration, depression, psychiatric disorders, serotonin, BDNF, stress,
polyglutamine disease
INTRODUCTION
Huntington’s disease (HD) is a progressive neurodegenerative dis-
order that affects mood, cognition, and movement. HD provides a
unique opportunity to study pathogenesis from its earliest stages,
as the genetic cause of this autosomal dominant disease, with its
array of divergent symptoms, is known. HD is caused by an abnor-
mal expansion mutation of a tract of CAG trinucleotide tandem
repeats close to the 5′ end of the huntingtin gene on chromosome 4
(The Huntington’s Disease Collaborative Research Group, 1993).
HD was first described by the physician George Huntington in
1872, and our understanding of the mechanisms underlying HD
has increased exponentially in the 20 years since the tandem repeat
expansion in huntingtin was found to be the causative gene muta-
tion. Despite this, a cure for this disease remains elusive. In light of
this, much attention has been focused on symptom management.
As a late onset disease, alleviation of especially early symptoms
can greatly lengthen and improve the largely normal and pro-
ductive periods of patients’ lives. HD presents with a classic triad
of relentlessly progressive symptoms. Diagnosis is based on the
appearance of motor symptoms, which most commonly appear
in patients in the fourth or fifth decade of life. Some rare cases of
juvenile onset are seen, with motor symptoms manifesting dur-
ing or prior to teenage years; however juvenile onset HD, which is
caused by exceptionally long CAG repeat expansions, accounts for
only about 5% of all HD cases (Nance and Myers, 2001). Complet-
ing the triad are cognitive and psychiatric symptoms, which can
arise years, often decades, prior to the inception of motor symp-
toms. There are also a plethora of non-CNS, peripheral symptoms,
although it is not yet clear whether specific symptoms originate
from cellular dysfunctions in central and/or peripheral tissues (van
der Burg et al., 2009).
Psychiatric symptoms abound in HD (Leroi et al., 2002),
including psychosis (Lovestone et al., 1996), irritability, anxiety,
apathy (van Duijn et al., 2007), and obsessive and compulsive
symptoms (Beglinger et al., 2008; van Duijn et al., 2008). However,
depression is among the most prevalent of psychiatric symptoms,
with a lifetime prevalence of major depression reported to be up to
and over 50% in patients; moreover, depression is often diagnosed
years if not decades prior motor symptom onset (Shiwach, 1994;
Naarding et al., 2001; Paulsen et al., 2001, 2005; Duff et al., 2007;
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van Duijn et al., 2008; Gargiulo et al., 2009). This occurrence is
hugely disproportionate when compared to lifetime prevalence of
major depression in the general population, which has been found
to be around 15% (Hasin et al., 2005; Kessler et al., 2005).
More than merely prevalent, depression has been rated by
patients as one of the most debilitating symptoms of HD, affect-
ing perceived quality of life more so than motor or even cognitive
aspects of the disease (Ho et al., 2009). Depression increases the
risk of suicide (Jensen et al., 1993; Harris and Barraclough, 1998;
Cavanagh et al., 2003). In HD, almost 30% of patients attempt sui-
cide at least once and death due to suicide among HD patients is
four times that of the normal populace – a similar rate of death by
suicide to that of those suffering from affective disorders (Farrer,
1986; Inskip et al., 1998). The presence of depression also leads to
negative collateral effects such as the hastening of cognitive decline
(Nehl et al., 2001; Smith et al., 2012). Whilst there is currently
no cure available for HD, depression is largely seen as treatable.
However, understanding of the etiology and pathophysiology of
this early-onset symptom is required to allow early detection of
depression and to apply the most suitable treatments.
Huntington’s disease is the most notorious of a group of
neurodegenerative diseases caused by an expansion of a CAG
trinucleotide repeat encoding poly-glutamine (poly-Q). Other dis-
eases in this group include dentatorubropallidoluysian atrophy
(DRPLA), spinocerebellar ataxia type 3 (SCA-3), spinal bulbar
muscular atrophy (SBMA), and spinocerebellar ataxia types 1, 2,
6, 7, and 17 (David et al., 1997; Kakizuka, 1997; Koshy and Zoghbi,
1997; Robitaille et al., 1997; Ross, 1997; Nakamura, 2001; Naka-
mura et al., 2001). SCA patients show depression prevalence of
between 15 and 17% in a large study with 526 genetically con-
firmed and clinically affected patients (117 SCA1, 163 SCA2, 139
SCA3, and 107 SCA6) (Schmitz-Hübsch et al., 2011), a rate similar
to the prevalence in the general population (∼15%) and certainly
less than that seen in HD. Other members of this group are very
rare and studies have not been done specifically examining rates of
depression. The overrepresentation of depression in HD may be
due to the neurological importance of the huntingtin protein, its
ubiquitousness and the subsequent consequences of the mutation.
Whilst the link between the length of CAG expansion and speed
of deterioration has been established, evidence from the literature
does not support the idea that depression in HD is affected by the
length of CAG repeats. In a study with a cohort of 79 HD patients,
no correlations were observed between CAG repeat length and per-
sonality change, psychosis, depression, or non-specific alterations
(Weigell-Weber et al., 1996). No relationship was discerned even
after correcting for predicted age of neurological onset in neu-
rologically asymptomatic patients (Berrios et al., 2001). A more
recent study examining 72 HD patients found that whilst the num-
ber of CAG repeats associated negatively with the age of onset of
psychiatric disorders, neither the probability of developing psy-
chiatric disorders nor the severity of psychiatric symptoms was
correlated with the number of CAG repeats (Vassos et al., 2008).
It therefore seems that although higher repeat number is associ-
ated with faster disease progression as a whole, it is insufficient to
induce depression.
Although the ultimate cause of depression in HD may be differ-
ent from that of depression in the HD gene-negative population
(which we will refer to forthwith as “clinical depression”), recent
research has shown that there are certainly perceptible similarities
in the symptoms and even physiological anomalies. These simi-
larities are worth examining as they may hold clues to the etiology
of depression in HD and may be informative in establishing how
best to treat this debilitating affective disorder. Various aspects
of HD pathogenesis, including disrupted transcription, traffick-
ing, signaling, homeostasis, synaptic and neuronal function, have
been recently reviewed (Milnerwood and Raymond, 2010; Ray-
mond et al., 2011; Ross and Tabrizi, 2011; Nithianantharajah
and Hannan, 2012). Here, we discuss potential molecular and
cellular mechanisms specifically involved in the etiology of depres-
sion in HD. This includes evidence implicating the dysregulation
of serotonergic signaling, alteration of hypothalamic-pituitary-
adrenal (HPA)-axis activity, and disruption of BDNF expression
and trafficking as key pathogenic processes.
DIAGNOSING DEPRESSION IN HD
Notwithstanding evidence of overwhelming prevalence of psy-
chiatric symptoms, treatment of psychopathologies in HD has
been scantly examined. Studies of the efficacy of various drugs
in treating these symptoms have been few and far between, mostly
with small cohorts, often case reports of a single patient with
no controls (Naarding et al., 2001). While conventional antide-
pressants have been applied in the treatment of depression in
HD, the effectiveness of different types of antidepressants, doses,
treatment durations, and other factors have not been thoroughly
examined. Having a different origin of disease, i.e., the mutation
in the huntingtin gene, it is possible that disparities exist in HD
which may translate to more efficacious treatment strategies. For
instance, a study has found that passivity is a risk factor to ear-
lier disease onset versus patients who were more active (Trembath
et al., 2010). This reflects findings in mouse models where trans-
genic mice raised in enriched cages which provided enhanced
sensory stimulations were rescued from depressive-like behav-
ioral phenotypes seen in mice raised in standard cages (Pang
et al., 2009; Du et al., 2012; Renoir et al., 2013). This suggests
enhanced engagement and participation may have benefits in the
treatment of depression. Little has been done with regards to
behavioral therapy in HD but a study has shown that remotiva-
tional therapy improving quality of life of HD patients (Sullivan
et al., 2001). A recent study on the use of antidepressants in
pre-onset HD gene carriers found that about 22% of 787 pro-
dromal patients are already on antidepressants, much more than
in the control group, with around 13% on antidepressants (Rowe
et al., 2012). However, a consensus on the prevalence of depres-
sion in HD has yet to be reached. The inconsistency in rates of
depression reported between different studies is due to a variety
of factors such as small sample sizes, differences in methodolo-
gies utilized, lack of control groups, and differences in the disease
stages of participants (van Duijn et al., 2007). In particular, the
usage of different assessment tools [Unified Huntington’s Dis-
ease Rating Scale (UHDR), Diagnostics and Statistics Manual
of Mental Disorders (DSM), Neuropsychiatric Inventory (NPI),
Beck Depression Inventory-II (BDI-II), Hamilton Rating Scale
for Depression (Ham-D), Hospital Anxiety and Depression Scale
(HADS), Depression Intensity Scale Circles (DISCs)] have resulted
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in very disparate estimations of the prevalence of depression in
HD, ranging from 33 to 69%.
This large variation highlights the endogenous differences
between how depression manifests with and without the HD gene
mutation, causing the use of tools not tailored for depression in
HD to produce inconsistent results. For example, standard rating
scales for clinical depression contain items relating to symptoms of
HD that are present regardless of the presence or absence of depres-
sion and therefore may skew the diagnosis. Weight loss and sleep
disturbances are items included in many diagnostic tools as symp-
tomatic of depression even though they are common symptoms
in HD patients without depression. Therefore these symptoms
may well be nothing but red herrings if included for diagnosis of
depression in HD. Scales that contain less “somatic” items, such as
the HADS and the DISCs were better able to accurately identify
depression in HD (De Souza et al., 2010). Comparison between
the BDI-II and the Ham-D found that the items best able to dis-
criminate depression in HD patients, other than depressed mood,
which had high correlations [correlation coefficient (r)= 0.834
for the BDI and 0.917 for the Ham-D], are those items measur-
ing thoughts and attitudes around mood such as “discouraged
about the future” (r = 0.653) and “satisfaction in life” (r = 0.64).
Weight loss (r = 0.193 for BDI and 0.128 for Ham-D), loss of
appetite (r = 0.319 for BDI, 0.297 for Ham-D), and other vege-
tative symptoms associated with clinical depression were, on the
other hand, poor indicators of depression in HD (Rickards et al.,
2011). Depression is notoriously heterogeneous in its presentation
and these findings suggest possible dominance of a different cluster
of symptoms in HD compared to most clinical depression patients.
Accurate discriminators of depression in HD are required for bet-
ter screening, diagnosis, and the gaging of treatment efficacy; areas
that have not so far been systematically studied. Whether or not
the differences reflected in the screening tools point to underly-
ing pathophysiological divergence between depression in HD and
clinical depression require further investigations. Besides the obvi-
ous consequences of depression itself, another important reason
for the accurate and early detection of depression in HD is that
depression has the negative effects of hastening cognitive decline
and correlates with poorer cognitive performance in prodromal
patients (Nehl et al., 2001; Smith et al., 2012), suggesting that ear-
lier intervention can prolong the functional years of a patient’s
life.
It is tempting to speculate, and indeed has been a predominant
view, that depression in HD is a natural consequence to the reactive
stress induced by the knowledge of being at risk of inheriting the
disease and/or of positive genetic or clinical diagnosis of HD (Shi-
wach and Norbury, 1994). Whilst psychosocial stress undoubtedly
adds to the psychological burden inducing depression (Codori
et al., 2004; Larsson et al., 2006), it alone is now regarded as insuf-
ficient to fully account for the psychiatric co-morbidity. Prior to
clinical onset, HD gene-positive carriers presented a higher cur-
rent prevalence of major depression despite being ignorant of
their gene status at the time of psychiatric assessment (Horowitz
et al., 2001; Julien et al., 2007). That overrepresentation suggests
that depression in HD patients is a behavioral manifestation of
early neuropathology. Interestingly, the greater susceptibility of
females to developing depression in the general population is also
apparent within the HD population (Zielonka et al., 2012). These
clinical aspects have been recapitulated by studies of the R6/1
transgenic and knock-in HdhQ111 mouse models (that are by
definition unaware of their gene status) which report a female-
specific depression-like behavioral phenotype (Pang et al., 2009;
Pouladi et al., 2009; Du et al., 2012; Orvoen et al., 2012; Renoir et al.,
2012), circumventing the caveat of psychosocial stress. Whilst sex-
ual dimorphism has been reported in the CAG(n51) transgenic
HD rats, the nature of the affective dysfunction in this model
is less clear (Bode et al., 2008; Faure et al., 2011). Depressive-like
behaviors have also been identified in the YAC transgenic HD mice
(Pouladi et al., 2009), suggesting that it is a fundamental aspect of
HD phenotypes. The study of other rodent models of HD might be
relevant for the understanding of other specific psychiatric aspects
of HD such as anxiety (Orvoen et al., 2012; Abada et al., 2013).
Although the pathophysiology leading to depression in HD
arises from a different source than those of clinical depression,
the successes of antidepressant treatments in ameliorating depres-
sion in HD, albeit mostly from case studies, suggest similarities in
the underlying pathophysiology. Therefore it is important to take
advantage of the extensive knowledge garnered in the study of clin-
ical depression and to compare the two diseases in order to apply
the most effective and tailored treatment for depression in HD.
THE SEROTONERGIC SYSTEM
Symptomatic treatment of depression in HD and the efficacy of
the range of antidepressant drugs often prescribed to HD patients
have not been thoroughly examined. Case studies report bene-
fits of selective serotonin reuptake inhibitors (SSRIs), selective
noradrenergic reuptake inhibitors (SNRIs) (venlafaxine), atyp-
ical antipsychotics (olanzepine), monoamine oxidase inhibitors
(MAOI), tetracyclic, and tricyclic antidepressants on small num-
bers of patients (Patel et al., 1996; Squitieri et al., 2001; Bonelli
et al., 2003; Ciammola et al., 2009). A study of 26 HD patients
with diagnoses of major depression treated with venlafaxine for
4 weeks showed significant improvement albeit a high rate of side
effects such as irritability (Holl et al., 2010). In a more recent study
by Rowe et al. (2012) of 787 prodromal HD participants, it was
reported that 20% of prodromal patients were prescribed anti-
depressants with the vast majority using SSRIs (e.g., paroxetine,
fluoxetine, and sertraline). However, the effectiveness SSRIs ver-
sus other types of antidepressants in diminishing the depression
symptoms has yet to be specifically documented. Indeed the over-
all effectiveness of SSRI interventions in treating depression in HD
has not been studied despite its frequent use.
Dysregulation of the serotonin (5-HT) signaling system has
long been scrutinized in the field of clinical depression as an
etiological cause (Castro et al., 1998; Yohrling et al., 2002). Com-
promising the 5-HT system affects its downstream elements; 5-HT
upregulates the expression of cyclic adenosine monophosphate
(cAMP) (Vaidya and Duman, 2001), which ultimately results in the
activation of cAMP response element-binding protein (CREB). A
loss of CREB signaling impairs adult hippocampal neurogenesis
and disrupts normal hippocampal function (Jacobs et al., 2000;
Urani et al., 2005), both of which have been proposed to be key
pathologies of depression (Petersen et al., 2008; Lucassen et al.,
2010). Based on findings from animal models, CREB signaling in
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HD is also disrupted, due to sequestration of its binding partner,
CREB binding protein (CBP). Thus, this is a common molecular
pathology that the disease shares with depression, and one which,
along with the target gene BDNF as described below, is likely to
mediate the deficits in hippocampal neurogenesis which is the
cellular consistently observed in animal models of HD. Chronic
treatment of different mouse models of HD with a variety of SSRIs
have been found to rescue the neurogenesis deficits but there has
yet to be a study demonstrating a possible rescue of neurogenesis
through modulation of CREB signaling. That would be an inter-
esting avenue of investigation for the future since compounds that
increase phosphorylation of CREB and cAMP levels are reportedly
associated with a rescue of cognitive deficits in the R6/1 transgenic
mouse model (Giralt et al., 2013).
Serotonin reuptake inhibitors work in part by desensitizing 5-
HT1A autoreceptors (Dawson et al., 2002; Rossi et al., 2008), which
act to inhibit 5-HT production. Desensitization of these autore-
ceptors therefore increases 5-HT neurotransmission (Blier et al.,
1998). It was also found that a single nucleotide polymorphism
(SNP) on the promoter of 5-HT1A receptor which leads to the
over-expression of 5-HT1A autoreceptors resulted in increased
susceptibility to developing major depression in those with the
mutation (Albert and Francois, 2010). As levels of 5-HT in the
human brain can only be measured post-mortem, markers are
used in patients to reflect 5-HT levels. One of these is measuring
the primary metabolite of 5-HT, 5-hydroxyindoleacetic acid (5-
HIAA) in the cerebrospinal fluid (CSF), which is deemed to reflect
brain 5-HIAA levels (Wester et al., 1990). It has been found that
5-HIAA is reduced in the CSF of a sizeable proportion of patients
with major depression, a finding replicated by post-mortem studies
(Asberg, 1976; Asberg et al., 1976; van Praag and Plutchik, 1984;
Roy et al., 1989). Reduced 5-HIAA levels have also been reported
in HD patients, which is a clear indicator that there is a dysreg-
ulation of serotonin metabolism in HD (Caraceni et al., 1977;
Jongen et al., 1980). Closely related, monoamine oxidase A, an
enzyme that metabolizes 5-HT thereby decreasing the amount of
available 5-HT, was elevated significantly in many brain regions of
depressed patients (Meyer et al., 2006). This abnormal increase in
metabolism of 5-HT has similarly been documented in the puta-
men and substantia nigra pars compacta of the basal ganglia, and
in the pons of HD brains through quantitative enzyme radioauto-
graphy (Richards et al., 2011). Interestingly, platelet monoamine
oxidase activity was reported to be unchanged in HD patients
with overt symptoms (Markianos et al., 2004) which suggests
a dissociation between central and peripheral pathology in HD.
Tryptophan, an essential amino acid from which serotonin is syn-
thesized, has also been found to be reduced in a large proportion
of patients with depression (Moller et al., 1983; Quintana, 1992).
Experimentally induced tryptophan depletion via a special diet
resulted in rapid relapse in remitted depression patients hours after
ingestion of diet (Delgado et al., 1990). Plasma total and protein-
bound tryptophan levels were found to be reduced in HD patients
(Belendiuk et al., 1980) and while oral tryptophan administration
increases blood 5-HT levels in healthy individuals, this response
not observed in HD patients which is a further demonstration of a
disease-associated impairment of 5-HT metabolism (Christofides
et al., 2006). A recent study looking at the raphe nucleus, where
5-HT synthesis occurs, found a significant correlation between
the level of depression in HD patients and stem raphe echogenic-
ity using transcranial sonography (Krogias et al., 2011). This is
similar to what is seen in clinical depression patients (Walter et al.,
2007), further strengthening the evidence that an abnormality in
5-HT production may underlie both diseases. Recent work on
compounds which influence tryptophan metabolism rescue neu-
rodegeneration in the R6/2 mouse model of HD (Zwilling et al.,
2011) but the effectiveness of such compounds to treat depressive
behaviors have yet to be determined.
Besides changes to 5-HT levels, dysregulation of the receptors
of 5-HT has also been implicated in depression. Major depres-
sion has been implicated with increased 5-HT1A autoreceptor
density in the dorsal raphe nucleus (Stockmeier et al., 1998).
Reduced post-synaptic 5-HT1A/2 receptor function has also been
linked with depression with patients who had suffered major
depression exhibiting global reduction in 5-HT1A and 5-HT2A
receptor binding (Drevets et al., 1999, 2007; Messa et al., 2003;
Moses-Kolko et al., 2008). This is reflected in animal models
where genetic 5-HT1A receptor knock-out mice showed pheno-
types of anxiety (Heisler et al., 1998; Parks et al., 1998; Ram-
boz et al., 1998) whereas over-expression of 5-HT1A receptor
reduced anxiety-related behaviors (Kusserow et al., 2004). In post-
mortem HD brains, reduced 5-HT1 receptor binding has been
reported in the putamen, hippocampus (Cross et al., 1986), and
in the basal ganglia and substantia nigra (Waeber and Palacios,
1989). Similar reductions in 5-HT1A receptor binding have been
reported in the R6/2 transgenic mouse model, as well as a marked
decrease in enzymatic activity of tryptophan hydroxylase (TPH)
activity (the rate limiting enzyme for the biosynthesis of 5-HT)
(Yohrling et al., 2002). The decrease in receptor binding is likely
attributable to down-regulation of mRNA levels of various 5-
HT receptors which is evident in R6/1 HD mice (Pang et al.,
2009). All these culminate in abnormal physiological responses
to the administration of 5-HT1A receptor agonist 8-OH-DPAT by
R6/1 HD mice (Renoir et al., 2011a, 2012), thereby demonstrating
how molecular neuropathology manifests as disease pathophys-
iology. Interestingly, chronic application of the SSRI sertraline
was able to correct the hypersensitivity of the 5-HT1A autore-
ceptor in female R6/1 mice as well as depression-like phenotype
(Renoir et al., 2012), suggesting an etiological link between distur-
bances to the 5-HT system with the HD-associated depression-like
phenotype.
THE HPA-AXIS AND STRESS RESPONSES
The HPA-axis is the major endocrine system responsible for stress
adaptation. Stress activates the axis, resulting in the production of
the stress hormone cortisol (corticosterone in rodents) (Papadim-
itriou and Priftis, 2009). Abnormally elevated HPA-axis activity is
one of the most replicated biological findings in major depression
(Pariante and Lightman, 2008; Stetler and Miller, 2011). Cortisol
levels are usually tightly regulated because prolonged exposure to
cortisol is damaging to the brain: reducing neurogenesis (Cameron
and Gould, 1994; Wong and Herbert, 2006; Brummelte and Galea,
2010) and increasing apoptosis in the hippocampus (Sapolsky,
1986; Crochemore et al., 2005; Andrés et al., 2006; Liu et al., 2011)
resulting in atrophy in the hippocampus of rats (Woolley et al.,
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1990) and monkeys (Sapolsky et al., 1990) as well as neuronal
atrophy (Cerqueira et al., 2005a) and volume reduction in the pre-
frontal cortex (Cerqueira et al., 2005b). Dysregulation of the 5-HT
neurotransmission has been linked with the HPA-axis abnormal-
ities (Hery et al., 2000; Froger et al., 2004). The serotonin system
is able to modulate anxiety and depression (Meaney et al., 1994;
Ramboz et al., 1998; Harada et al., 2008; Brummett et al., 2012),
possibly by regulating the HPA-axis through influencing glucocor-
ticoid receptor (GR), whose activation is important in regulating
the 5-HT system both in vivo and in vitro (Lanfumey et al., 2000;
Erdeljan et al., 2001; Wang et al., 2009; Falkenberg and Rajee-
van, 2010; Belay et al., 2011). For example, it has been found that
serotonin neurotransmission is modulated by HPA-axis activity,
with GR activation increasing 5-HT1A signaling (Hesen and Joels,
1996). Adrenalectomy reduced dentate gyrus neuronal morphol-
ogy and this effect was reversed by using the 5-HT1A agonist
ipsapirone (Huang et al., 1997). But sustained elevation of corti-
costeroid significantly reduced 5-HT1A receptor mRNA level as
well as 5-HT1A binding density in the hippocampus and this
is reversed by chronic administration of antidepressants (Lopez
et al., 1998).
Studies have also described HPA-axis hyperactivity in HD
patients. Earlier studies with small sample sizes found higher basal
cortisol levels in moderate stage HD patients compared to controls
at both morning (Leblhuber et al., 1995) and evening (Heuser
et al., 1991). More recently, hyperactivity of the HPA-axis has
been found in a small sample of clinically diagnosed, early stage
HD patients compared to controls, with higher 24 h cortisol pro-
duction, particularly in the morning and early afternoon periods
(Aziz et al., 2009). Examining salivary cortisol in pre-symptomatic
HD patients in comparison to controls, subtle but altered cortisol
awakening responses were found, with higher cortisol concentra-
tion in patients at early morning periods, just after awakening (van
Duijn et al., 2010). This indicates that HPA-axis dysregulation is an
early pathophysiology in HD. However, another study with a com-
paratively large sample of patients found increased urine cortisol
levels but only in moderate to late clinically diagnosed patients
whereas pre-symptomatic and early stage patients did not display
any differences in urine cortisol compared to 68 healthy controls
(Björkqvist et al., 2006). But it is worthy to note that in this study,
samples were collected in a narrow time window (14:00–17:00),
when cortisol level is ebbing, leaving the possibility that the dif-
ference identified in the previous studies was masked in the early
stage patients examined. Furthermore, analysis of patients was
confounded by limitations to recruitment such as imbalance of
gender (or indeed disregarding gender as a factor), differences in
stages of disease progression as well as environmental confounders
such as smoking, alcoholism, depression, and use of psychotropic
medications.
Increased baseline corticosterone was initially found in R6/2
mice from an early age (Björkqvist et al., 2006). However, because
of their rapid motor onset and deterioration, the R6/2 model is
not an optimal one for examining pre-motor onset symptoms and
pathophysiologies. Recently, it was found that at a pre-motor onset
age, female R6/1 mice exhibit increased corticosterone release after
physiological and pharmacological stresses whilst baseline levels
did not differ between WT and R6/1 females (Du et al., 2012).
This is more akin to what is seen in early, pre-motor symptomatic
HD patients with little change in baseline cortisol levels, suggesting
that in prodromal patients, differences may only become appar-
ent when the HPA-axis is induced by stressors. Interestingly, the
sex-dimorphic display of this physiological abnormality correlates
with prior findings of depression-like behavioral phenotypes in
pre-motor onset female R6/1 mice that were also absent in the
males of the same age (Pang et al., 2009; Renoir et al., 2011b).
Curiously, using pharmacological means as well as in vitro analy-
sis, it was found that the source of the hyperactivity in the female
R6/1 mice is the adrenal gland (Du et al., 2012). Studies examin-
ing the adrenal glands in HD have so far been scant. However, this
finding raises the possibility of an early peripheral change which
may influence central brain function. More research is required to
examine the HPA-axis of HD patients in terms of its regulation and
response to stress. Whilst adrenal hyperplasia has been found in
victims of suicide (Szigethy et al., 1994) and a few studies reporting
increased adrenal volume in depressed patients compared to con-
trols, the lack of numbers and heterogeneity between studies makes
it hard to draw useful conclusions about the role adrenal-specific
pathology may play in the development of depression (Kessing
et al., 2011).
BDNF AND NEUROTROPHIN SIGNALING
Depression is a complex affective disorder and is thought to result
at least partially from an inability of the brain to make appropriate
adaptations to environmental stressors, and may involve impaired
neural plasticity (Duman et al., 2000; Duman, 2002; Manji et al.,
2003; Czeh and Simon, 2005). This is evidenced by studies show-
ing altered brain structures in depression subjects such as reduced
cell number, cell density, and body size as well as reduced glial
density in frontal cortical and hippocampal brain regions (Ongur
et al., 1998; Cotter et al., 2001; Beasley et al., 2002; Rajkowska,
2002). These observations led to the hypothesis that a loss of neu-
rotrophic factors, which are vital for the survival, development,
and maintenance of neurons (Lewin and Barde, 1996; McAllister,
2001) as well as regulating synaptic and morphological plasticity
(McAllister et al., 1999; Thoenen, 2000), is directly involved in the
pathophysiology of depression and that its restitution may lie at the
heart of successful treatment (Altar, 1999; Duman, 2004). Indeed,
recently it was found that HD patients exhibited a significant
decrease in peripheral BDNF gene expression (Krzyszton-Russjan
et al., 2012). HD patients (Ciammola et al., 2007) and rodent mod-
els of HD (Strand et al., 2007) also show reduced levels of BDNF
protein. Huntingtin has important roles in regulating both the
transcription (Zuccato et al., 2001) and trafficking (DiFiglia et al.,
1995; Gauthier et al., 2004) of BDNF, actions that are affected by
the mutation in HD.
BDNF helps support the survival and integrity of existing neu-
rons and encourage growth, migration, and differentiation of new
neurons and synapses in the central as well as peripheral nervous
systems (Cowansage et al., 2010). It also enhances neurogenesis
in the hippocampus (Zigova et al., 1998; Benraiss et al., 2001;
Pencea et al., 2001). The expression of BDNF is regulated via neu-
ronal activity through calcium mediated mechanisms (Tabuchi,
2008) whilst its receptor tyrosine kinase-coupled receptor (TrkB),
is also regulated in an activity-dependent manner (Nagappan
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and Lu, 2005). As compromised synaptic and structural plastic-
ity is significantly associated with depression, the importance of
BDNF in depression has therefore garnered considerable atten-
tion. Lower levels of BDNF in depression patients suggest a role
of BDNF in the pathogenesis of depression (Yoshimura et al.,
2010; Yoshida et al., 2012). Serum BDNF was found to be signif-
icantly reduced in antidepressant-naïve depression patients com-
pared to those who were treated with antidepressants and there
was a significant negative correlation between BDNF levels and
the Hamilton Rating Scale for Depression (Shimizu et al., 2003).
Hippocampal BDNF levels in post-mortem brains of depression
patients were found to be higher in those treated with antide-
pressants at time of death (Chen et al., 2001; Karege et al., 2005).
This suggests that antidepressants increase BDNF levels and may
account, at least in part, for their potency. In animal models, a
similar result was seen. It was found that early life stress low-
ers BDNF and alters stress sensitivity later in life (Cirulli et al.,
2009), whereas increases in BDNF, either via social enrichment or
direct infusion into the brain, was found to reduce susceptibil-
ity to depression-like behavior (Siuciak et al., 1997; Cirulli et al.,
2010).
However, studies also found that increases in BDNF through
communal nesting induced an anxiety phenotype by reducing
latency to immobility and increasing immobility time in the
forced-swim test (FST) (Branchi et al., 2006). Other studies exam-
ining the role of BDNF in depression have also found that het-
erozygous knock-out of BDNF did not alter anxiety profile on
the elevated-plus maze (Montkowski and Holsboer, 1997; Mac-
Queen et al., 2001; Gorski et al., 2003). BDNF heterozygotes or
mice expressing the dominant negative TrkB receptor TrkB.T1, did
not show any differences from WT mice in their performance on
the FST, therefore showing that reduced BDNF signaling does not
cause depression per se (Saarelainen et al., 2003). However, the fact
that a lack of BDNF signaling negated the effects of antidepressant
treatment argues that whilst it is not predictive of depression, it is
integral for the potency of antidepressant action.
BDNF seems to mediate the positive effect of several classes
of antidepressants including SSRIs, tricyclics, SNRI, and MAOI,
which have been found to increase BDNF in serum, cortical astro-
cytes, prefrontal cortex, and hippocampus (Duman and Mon-
teggia, 2006; Allaman et al., 2011; Molendijk et al., 2011). It is
also upregulated by exercise and environmental enrichment, con-
tributing to beneficial effects such as induction of cell survival,
proliferation, and dendritic development, leading to augmented
cognitive outcomes (Acheson et al., 1995; Cotman and Berchtold,
2002; Choi et al., 2009; Sun et al., 2010; Kazlauckas et al., 2011).
Environmental enrichment and exercise (voluntary wheel run-
ning) have been found to rescue BDNF deficits in R6/1 HD mice
as well as ameliorating affective, cognitive, and motor abnormal-
ities (van Dellen et al., 2000; Spires et al., 2004; Pang et al., 2006,
2009; Nithianantharajah et al., 2008; Zajac et al., 2010; Renoir et al.,
2013). A diet rich in omega-3 fatty acids, which has been shown to
have positive effects on depression (Freeman, 2009), also increases
BDNF levels in the hippocampus (Venna et al., 2009).
In BDNF-deficient mice, the behavioral effects of antide-
pressants were abolished (Saarelainen et al., 2003; Monteggia
et al., 2004). TrkB T1 over-expressing transgenic mice, which
show reduced TrkB activation in the brain, are resistant to the
effects of antidepressants (Saarelainen et al., 2003), whereas over-
expression of TrkB led to resistance to depression-like behav-
ior, with SSRI administration unable to further increase this
resistance (Koponen et al., 2005) indicating that TrkB signal-
ing is required for the behavioral benefits of antidepressants.
These findings suggest that BDNF may be a key molecule
involved in various antidepressant treatment strategies. A pos-
sible mechanism mediating the antidepressant-induced increase
of BDNF is the upregulated expression of CREB, a transcrip-
tion factor that upregulates BDNF and TrkB (Nibuya et al.,
1996). Interestingly, CREB-mediated transcription regulation
requires the aid of CBP, whose expression is downregulated
by mutant huntingtin (Kazantsev et al., 1999; Nucifora et al.,
2001).
Antidepressants are widely used in the treatment of HD patients
(Sackley et al., 2011). Recent studies suggest that chronic treatment
with the SSRIs fluoxetine or sertraline increased hippocampal
neurogenesis, ameliorated cognitive deficits, and depression-like
behavioral symptoms in R6/1 mice (Grote et al., 2005; Renoir
et al., 2012) and increased BDNF levels and neurogenesis in
R6/2 mice (Peng et al., 2008). Chronic antidepressant treatment
in depressed patients resulted in upregulation of CREB protein
expression (Nibuya et al., 1996), CREB phosphorylation (Saare-
lainen et al., 2003), BDNF (Chen et al., 2001), and TrkB (Bayer
et al., 2000) in the hippocampus. BDNF has been proposed to
be a mediator of the effects of antidepressants (Koponen et al.,
2005), by augmenting the survival and differentiation of adult-
born neurons in the dentate gyrus (Groves, 2007). These results
led to the hypothesis that depression in HD coincides with
decreased activity in the serotonin-CREB-BDNF-TrkB pathway,
resulting in cellular dysfunction and reduced neurogenesis in the
hippocampus.
The link between HPA-axis, depression, and BDNF has been
explored in rodent models of depression and given much atten-
tion. Social stress has been widely used as a useful model of
depression (Henn and Vollmayr, 2005). Stressors such as forced
immobilization (Smith et al., 1995) and social defeat (Pizarro
et al., 2004) were found to decrease BDNF expression in the hip-
pocampus and cortical and subcortical regions of rodent models.
Induced elevation of corticosterone, mimicking the effect of stress,
has also been associated with reduced levels of BDNF mRNA and
protein in the hippocampus and frontal cortex of rodent mod-
els (Schaaf et al., 1997, 1998; Chao et al., 1998; Dwivedi et al.,
2006). Adrenalectomy surgery caused an increase of BDNF in
the hippocampus (Chao et al., 1998), whilst chronic GR activa-
tion reduces both CREB phosphorylation and BDNF expression
(Focking et al., 2003). This suggests regulatory ability of glu-
cocorticoids on BDNF expression. GR was also found to inter-
act with the BDNF receptor TrkB and corticosterone reduces
TrkB-GR interaction, causing reduced BDNF-triggered glutamate
release and BDNF-stimulated PLC-γ (Numakawa et al., 2009).
Thus, taken together, increased HPA-axis activity may initiate a
chain reaction, leading to altered 5-HT signaling, reduced CREB-
mediated transcription of BDNF and damage to the hippocam-
pus and other brain regions, which in turn, reduces negative
feedback on the HPA-axis in a negative cycle (Figure 1). The
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FIGURE 1 | A schematic diagram illustrating potential molecular and
cellular mediators of HD pathogenesis, with a focus on serotonergic and
neurotrophin signaling as well as the HPA-dysfunction which may give
rise to depression and associated symptoms. The role of environmental
enrichment in ameliorating specific aspects of molecular, cellular, and
systems dysfunction is also illustrated. There are clearly many other molecular
and cellular candidates implicated in HD pathogenesis which are not shown in
this diagram, which outlines a specific hypothesis regarding the etiology of
depression in HD. 5-HT, serotonin; BDNF, brain-derived neurotrophic factor;
HD, Huntington’s disease; HPA-axis, hypothalamic-pituitary-adrenal axis.
molecular and cellular processes may be impacted by environ-
mental modulators, such as the cognitive stimulation and physical
exercise induced by environmental enrichment. Complex gene–
gene interactions and associated gene-environment interactions
are presumably responsible for the variable incidence of depres-
sion both within HD patients (where each tandem repeat expan-
sion mutation is embedded in a genome possessing a range of
genetic modifiers) and the general population. Elucidation of this
complexity at molecular, cellular, and systems levels will require
a new generation of sophisticated animal models and clinical
investigations.
SUMMARY
As a cure for HD remains elusive, effective strategies targeting
symptom management are of great interest. This is especially per-
tinent with early onset psychiatric and cognitive symptoms, which
tend to occur in the most productive years. Depression, being
both early onset and having devastating consequences, is a priority
target.
Collectively, HD shares certain hallmarks with a large portion
of clinical depression patients: namely, disturbances of the 5-HT
system, BDNF expression, and HPA-axis dysregulation. This is
not perhaps surprising as the use of conventional antidepressants
have shown to be equally efficacious in treating depression in HD.
However, due to the relentless deterioration of the brain seen
in HD, it is paramount to diagnose depression both early and
accurately in the hope of stemming the decline with appropriate
interventions. The inconsistent diagnostic results reflect the need
for a tailored diagnostic tool for HD, taking into account many
somatic symptoms such as weight loss which often seem to have
little to do with depression. Furthermore, besides antidepres-
sants such as SSRIs, other methods may be examined in detail
as potential therapeutics. Strategies such as exercise interventions,
occupational therapy, and other cognitive/behavioral treatments
are under-utilized in HD and worthy of systematic investiga-
tion, both on their own and as adjuncts to pharmacological
treatments.
Ultimately, the treatment of HD may require a sophisti-
cated understanding of the pathogenesis of psychiatric, cog-
nitive and motor symptoms, and the source of their het-
erogeneity in clinical populations. For example, it would be
expected that genetic polymorphisms/mutations which predis-
pose to depression in the general population might have addi-
tive effects on predisposition when combined with the HD
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mutation. Similarly, the kind of stressors which can trigger
depression in genetically vulnerable individuals might be equally
toxic for those who are HD gene-positive. A natural conse-
quence of such detailed insights into pathogenesis could be
pharmacogenomics, polypharmacy, and other tailored therapeutic
approaches to improve the lives of those suffering from HD and
depression.
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